Kura Oncology Key Executives
This section highlights Kura Oncology's key executives, including their titles and compensation details.
Find Contacts at Kura Oncology
(Showing 0 of )
Kura Oncology Earnings
This section highlights Kura Oncology's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-27 | N/A | N/A |
| Read Transcript | Q3 | 2024 | 2024-11-09 | N/A | N/A |
| Read Transcript | Q2 | 2024 | 2024-08-09 | N/A | N/A |
| Read Transcript | Q1 | 2024 | 2024-05-02 | $-0.56 | $-0.59 |
| Read Transcript | Q4 | 2023 | 2024-02-27 | $-0.56 | $-0.55 |
| Read Transcript | Q3 | 2023 | 2023-11-03 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-08-06 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2023-05-10 | $-0.54 | $-0.50 |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
$7.17
Stock Price
$579.01M
Market Cap
192
Employees
San Diego, CA
Location
Financial Statements
Access annual & quarterly financial statements for Kura Oncology, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $53.88M | $- | $- | $- | $- |
| Cost of Revenue | $- | $849.00K | $759.00K | $558.00K | $194.00K |
| Gross Profit | $53.88M | $-849.00K | $-759.00K | $-558.00K | $-194.00K |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $169.97M | $115.23M | $92.81M | $84.72M | $60.40M |
| General and Administrative Expenses | $77.11M | $50.57M | $47.05M | $46.54M | $31.50M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $77.11M | $50.57M | $47.05M | $46.54M | $31.50M |
| Other Expenses | $- | $- | $4.03M | $792.00K | $2.27M |
| Operating Expenses | $247.08M | $165.80M | $139.87M | $131.26M | $91.90M |
| Cost and Expenses | $247.08M | $165.80M | $139.87M | $131.26M | $91.90M |
| Interest Income | $22.85M | $14.72M | $4.25M | $1.21M | $2.80M |
| Interest Expense | $1.62M | $1.55M | $229.00K | $414.00K | $578.00K |
| Depreciation and Amortization | $23.70M | $849.00K | $759.00K | $558.00K | $194.00K |
| EBITDA | $-169.50M | $-164.96M | $-139.11M | $-129.71M | $-91.70M |
| EBITDA Ratio | -314.57% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-193.19M | $-165.80M | $-140.62M | $-131.82M | $-92.09M |
| Operating Income Ratio | -358.55% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $21.23M | $13.17M | $4.03M | $792.00K | $2.27M |
| Income Before Tax | $-171.97M | $-152.63M | $-135.84M | $-130.47M | $-89.62M |
| Income Before Tax Ratio | -319.15% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $2.02M | $- | $229.00K | $-558.00K | $-194.00K |
| Net Income | $-173.98M | $-152.63M | $-136.07M | $-129.91M | $-89.43M |
| Net Income Ratio | -322.89% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-2.02 | $-2.08 | $-2.03 | $-1.96 | $-1.68 |
| EPS Diluted | $-2.02 | $-2.08 | $-2.03 | $-1.96 | $-1.68 |
| Weighted Average Shares Outstanding | 86.16M | 73.23M | 66.99M | 66.35M | 53.08M |
| Weighted Average Shares Outstanding Diluted | 86.16M | 73.23M | 66.99M | 66.35M | 53.08M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $53.88M | $- | $- | $- | $1.27M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $202.00K | $234.00K | $214.00K | $216.00K | $213.00K | $206.00K | $206.00K | $- | $183.00K | $177.00K | $166.00K | $160.00K | $124.00K | $108.00K | $- | $- | $- | $- |
| Gross Profit | $53.88M | $- | $-202.00K | $-234.00K | $1.06M | $-216.00K | $-213.00K | $-206.00K | $-206.00K | $- | $-183.00K | $-177.00K | $-166.00K | $-160.00K | $-124.00K | $-108.00K | $- | $- | $- | $- |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 83.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $52.27M | $41.70M | $39.73M | $36.27M | $32.53M | $29.33M | $28.18M | $25.19M | $22.67M | $24.97M | $24.26M | $20.91M | $20.96M | $22.37M | $21.07M | $20.32M | $17.52M | $16.60M | $13.70M | $12.57M |
| General and Administrative Expenses | $24.07M | $18.18M | $16.68M | $18.18M | $14.23M | $13.14M | $11.82M | $11.37M | $12.49M | $11.62M | $11.07M | $11.87M | $12.08M | $11.31M | $12.57M | $10.57M | $8.81M | $7.59M | $7.48M | $7.62M |
| Selling and Marketing Expenses | $- | $- | $-202.00K | $-234.00K | $-214.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $24.07M | $18.18M | $16.48M | $17.95M | $14.02M | $13.14M | $11.82M | $11.37M | $12.49M | $11.62M | $11.07M | $11.87M | $12.08M | $11.31M | $12.57M | $10.57M | $8.81M | $7.59M | $7.48M | $7.62M |
| Other Expenses | $-22.45M | $- | $- | $- | $-5.33M | $- | $2.83M | $2.50M | $2.04M | $- | $- | $- | $295.00K | $- | $- | $8.00K | $173.00K | $12.00K | $12.00K | $15.00K |
| Operating Expenses | $53.88M | $59.88M | $56.20M | $54.22M | $46.55M | $42.47M | $40.00M | $36.57M | $35.16M | $36.59M | $35.33M | $32.78M | $33.04M | $33.68M | $33.65M | $30.90M | $26.33M | $24.19M | $21.17M | $20.20M |
| Cost and Expenses | $53.88M | $59.88M | $56.40M | $54.45M | $46.76M | $42.47M | $40.00M | $36.57M | $35.16M | $36.59M | $35.33M | $32.78M | $33.04M | $33.68M | $33.65M | $30.90M | $26.33M | $24.19M | $21.17M | $20.20M |
| Interest Income | $5.66M | $5.89M | $5.97M | $5.33M | $4.37M | $4.28M | $3.22M | $2.86M | $2.27M | $1.09M | $564.00K | $329.00K | $295.00K | $311.00K | $290.00K | $302.00K | $305.00K | $559.00K | $818.00K | $1.12M |
| Interest Expense | $403.00K | $412.00K | $406.00K | $398.00K | $394.00K | $404.00K | $387.00K | $364.00K | $229.00K | $- | $564.00K | $329.00K | $- | $- | $306.00K | $108.00K | $144.00K | $146.00K | $144.00K | $144.00K |
| Depreciation and Amortization | $204.00K | $208.00K | $202.00K | $234.00K | $214.00K | $216.00K | $213.00K | $206.00K | $206.00K | $193.00K | $183.00K | $177.00K | $166.00K | $160.00K | $124.00K | $108.00K | $108.00K | $74.00K | $6.00K | $1.13M |
| EBITDA | $-16.59M | $-59.68M | $-50.23M | $-48.89M | $-42.18M | $-37.98M | $-36.57M | $-33.50M | $-32.68M | $-35.31M | $-34.59M | $-32.28M | $-32.58M | $-33.21M | $-33.45M | $-30.48M | $-25.91M | $-23.55M | $-20.33M | $-19.07M |
| EBITDA Ratio | -30.79% | 0.00% | 0.00% | 0.00% | -3665.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $- | $-59.88M | $-56.40M | $-54.45M | $-46.76M | $-38.60M | $-40.00M | $-36.77M | $-35.36M | $-36.59M | $-34.77M | $-32.45M | $-32.74M | $-33.68M | $-33.65M | $-30.90M | $-26.33M | $-24.19M | $-21.17M | $-20.20M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -3682.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $-17.20M | $5.48M | $5.57M | $4.93M | $3.98M | $3.87M | $2.83M | $2.50M | $2.04M | $1.09M | $564.00K | $329.00K | $295.00K | $311.00K | $-16.00K | $202.00K | $173.00K | $425.00K | $686.00K | $990.00K |
| Income Before Tax | $-17.20M | $-54.40M | $-50.84M | $-49.52M | $-42.79M | $-38.60M | $-37.17M | $-34.07M | $-33.11M | $-35.50M | $-34.77M | $-32.45M | $-32.74M | $-33.37M | $-33.66M | $-30.69M | $-26.16M | $-23.77M | $-20.49M | $-19.21M |
| Income Before Tax Ratio | -31.92% | 0.00% | 0.00% | 0.00% | -3368.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $2.02M | $- | $- | $190.72K | $2.88M | $404.00K | $-213.00K | $-3.07M | $229.00K | $1.09M | $564.00K | $329.00K | $-166.00K | $311.00K | $290.00K | $116.00K | $-108.00K | $158.00K | $-674.00K | $-975.00K |
| Net Income | $-19.22M | $-54.40M | $-50.84M | $-49.52M | $-42.79M | $-38.60M | $-37.17M | $-31.00M | $-33.34M | $-35.50M | $-35.33M | $-32.78M | $-32.74M | $-33.37M | $-33.66M | $-30.69M | $-26.16M | $-23.77M | $-20.49M | $-19.21M |
| Net Income Ratio | -35.66% | 0.00% | 0.00% | 0.00% | -3368.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.22 | $-0.63 | $-0.59 | $-0.59 | $-0.55 | $-0.50 | $-0.53 | $-0.45 | $-0.49 | $-0.53 | $-0.53 | $-0.49 | $-0.49 | $-0.50 | $-0.51 | $-0.46 | $-0.45 | $-0.42 | $-0.40 | $-0.42 |
| EPS Diluted | $-0.22 | $-0.63 | $-0.59 | $-0.59 | $-0.55 | $-0.50 | $-0.53 | $-0.45 | $-0.49 | $-0.53 | $-0.53 | $-0.49 | $-0.49 | $-0.50 | $-0.51 | $-0.46 | $-0.45 | $-0.42 | $-0.40 | $-0.42 |
| Weighted Average Shares Outstanding | 87.14M | 86.95M | 86.64M | 83.91M | 77.34M | 77.24M | 69.80M | 68.40M | 67.78M | 66.89M | 66.67M | 66.61M | 66.55M | 66.35M | 66.28M | 66.22M | 58.76M | 56.41M | 51.63M | 45.41M |
| Weighted Average Shares Outstanding Diluted | 87.14M | 86.95M | 86.64M | 83.91M | 77.34M | 77.24M | 69.80M | 68.40M | 67.78M | 66.89M | 66.67M | 66.61M | 66.55M | 66.35M | 66.28M | 66.22M | 58.76M | 56.41M | 51.63M | 45.41M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $224.46M | $37.32M | $51.80M | $90.67M | $325.49M |
| Short Term Investments | $502.93M | $386.64M | $386.18M | $427.29M | $307.83M |
| Cash and Short Term Investments | $727.39M | $423.96M | $437.99M | $517.96M | $633.32M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $17.43M | $8.52M | $8.44M | $2.93M | $7.94M |
| Total Current Assets | $744.83M | $432.48M | $446.43M | $522.29M | $637.29M |
| Property Plant Equipment Net | $7.49M | $8.85M | $6.38M | $8.25M | $8.36M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $210.00K | $210.00K | $210.00K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $7.84M | $7.60M | $3.29M | $3.31M | $1.35M |
| Total Non-Current Assets | $15.33M | $16.45M | $9.88M | $11.76M | $9.92M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $760.16M | $448.94M | $456.31M | $534.05M | $647.21M |
| Account Payables | $1.47M | $2.30M | $1.53M | $3.24M | $2.75M |
| Short Term Debt | $6.37M | $1.51M | $4.64M | $2.26M | $5.09M |
| Tax Payables | $2.06M | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $68.81M | $31.46M | $17.89M | $16.96M | $18.18M |
| Total Current Liabilities | $78.71M | $35.26M | $24.06M | $22.45M | $26.02M |
| Long Term Debt | $12.11M | $15.69M | $11.71M | $4.61M | $9.89M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $255.70M | $705.00K | $265.00K | $375.00K | $395.00K |
| Total Non-Current Liabilities | $267.81M | $16.40M | $11.97M | $4.99M | $10.28M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $346.52M | $51.66M | $36.03M | $27.44M | $36.31M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $8.00K | $7.00K | $7.00K | $7.00K | $7.00K |
| Retained Earnings | $-895.42M | $-721.44M | $-568.81M | $-432.97M | $-302.50M |
| Accumulated Other Comprehensive Income Loss | $764.00K | $-1.27M | $-8.03M | $-1.79M | $46.00K |
| Other Total Stockholders Equity | $1.31B | $1.12B | $997.11M | $941.36M | $913.35M |
| Total Stockholders Equity | $413.64M | $397.27M | $-568.81M | $-432.97M | $-302.50M |
| Total Equity | $413.64M | $397.27M | $-568.81M | $-432.97M | $-302.50M |
| Total Liabilities and Stockholders Equity | $760.16M | $448.94M | $-532.78M | $-405.53M | $-266.19M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $760.16M | $448.94M | $-532.78M | $-405.53M | $-266.19M |
| Total Investments | $502.93M | $386.64M | $386.18M | $427.29M | $307.83M |
| Total Debt | $16.59M | $17.20M | $14.02M | $6.88M | $14.98M |
| Net Debt | $-207.87M | $-20.12M | $-37.78M | $-83.80M | $-310.52M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $224.46M | $49.48M | $45.18M | $41.51M | $37.32M | $28.74M | $49.12M | $27.06M | $51.80M | $90.94M | $39.26M | $33.83M | $90.67M | $39.18M | $38.97M | $110.83M | $325.49M | $76.95M | $134.76M | $33.81M |
| Short Term Investments | $502.93M | $405.82M | $446.34M | $485.62M | $386.64M | $423.85M | $427.86M | $378.84M | $386.18M | $336.84M | $411.00M | $446.24M | $427.29M | $504.26M | $528.52M | $493.04M | $307.83M | $248.46M | $204.11M | $183.12M |
| Cash and Short Term Investments | $727.39M | $455.30M | $491.52M | $527.12M | $423.96M | $452.59M | $476.98M | $405.90M | $437.99M | $427.77M | $450.26M | $480.07M | $517.96M | $543.45M | $567.49M | $603.87M | $633.32M | $325.41M | $338.87M | $216.94M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $31.00K |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $17.43M | $7.89M | $8.25M | $10.71M | $13.15M | $7.32M | $8.67M | $10.55M | $8.44M | $17.23M | $19.06M | $13.92M | $2.93M | $10.92M | $12.28M | $13.66M | $7.94M | $7.00M | $6.63M | $8.33M |
| Total Current Assets | $744.83M | $463.19M | $499.77M | $537.84M | $432.48M | $459.92M | $476.98M | $416.45M | $446.43M | $436.39M | $459.79M | $487.03M | $522.29M | $548.90M | $573.63M | $610.71M | $637.29M | $328.91M | $342.19M | $221.13M |
| Property Plant Equipment Net | $7.49M | $7.42M | $7.92M | $8.41M | $8.85M | $9.34M | $5.19M | $5.76M | $6.38M | $7.02M | $7.26M | $7.72M | $8.25M | $8.72M | $7.74M | $8.02M | $8.36M | $8.81M | $8.76M | $805.00K |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $200.00K | $200.00K | $200.00K | $200.00K | $210.00K | $210.00K | $210.00K | $- | $210.00K | $210.00K | $210.00K | $210.00K | $210.00K | $210.00K | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $7.84M | $8.23M | $7.22M | $7.47M | $7.40M | $4.32M | $3.69M | $3.55M | $3.29M | $4.58M | $4.16M | $3.62M | $3.31M | $3.31M | $3.31M | $1.33M | $1.56M | $1.84M | $2.05M | $4.53M |
| Total Non-Current Assets | $15.33M | $15.65M | $15.35M | $16.07M | $16.45M | $13.85M | $9.09M | $9.53M | $9.88M | $11.60M | $11.64M | $11.55M | $11.76M | $12.24M | $11.26M | $9.56M | $9.92M | $10.66M | $10.81M | $5.33M |
| Other Assets | $- | $- | $- | $1 | $- | $-0 | $8.67M | $-0 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $760.16M | $478.84M | $515.12M | $553.91M | $448.94M | $473.77M | $494.74M | $425.98M | $456.31M | $447.99M | $471.43M | $498.58M | $534.05M | $561.14M | $584.89M | $620.26M | $647.21M | $339.57M | $353.00M | $226.46M |
| Account Payables | $1.47M | $3.01M | $2.06M | $7.53M | $2.30M | $1.76M | $2.34M | $3.29M | $1.53M | $1.75M | $1.40M | $1.34M | $3.24M | $2.88M | $2.40M | $958.00K | $2.75M | $814.00K | $786.00K | $2.45M |
| Short Term Debt | $4.49M | $3.41M | $3.78M | $1.36M | $3.01M | $3.36M | $4.69M | $4.66M | $2.32M | $4.61M | $4.58M | $4.55M | $2.26M | $2.25M | $1.98M | $5.10M | $5.09M | $4.40M | $3.50M | $1.00M |
| Tax Payables | $2.06M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $24.27M | $- | $- | $- | $- | $-1.76M | $-2.34M | $- | $- | $-2.30M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $46.42M | $33.96M | $27.61M | $23.37M | $29.95M | $22.40M | $16.87M | $11.28M | $20.21M | $18.39M | $11.90M | $11.84M | $16.96M | $16.80M | $16.91M | $19.08M | $18.18M | $16.49M | $14.27M | $11.10M |
| Total Current Liabilities | $78.71M | $40.37M | $33.45M | $32.27M | $35.26M | $27.52M | $23.90M | $19.23M | $24.06M | $24.75M | $17.87M | $17.73M | $22.45M | $21.93M | $21.29M | $25.14M | $26.02M | $21.70M | $18.55M | $14.55M |
| Long Term Debt | $12.11M | $13.22M | $14.42M | $15.61M | $15.69M | $15.74M | $10.70M | $11.21M | $11.71M | $3.08M | $3.60M | $4.11M | $4.61M | $5.10M | $4.75M | $8.70M | $9.89M | $11.02M | $11.77M | $6.50M |
| Deferred Revenue Non-Current | $253.91M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1.79M | $1.47M | $1.18M | $951.00K | $705.00K | $567.00K | $461.00K | $351.00K | $265.00K | $542.00K | $459.00K | $496.00K | $375.00K | $356.00K | $295.00K | $441.00K | $395.00K | $344.00K | $306.00K | $2.21M |
| Total Non-Current Liabilities | $267.81M | $14.69M | $15.59M | $16.56M | $16.40M | $16.31M | $11.16M | $11.56M | $11.97M | $3.62M | $4.06M | $4.61M | $4.99M | $5.46M | $5.05M | $9.14M | $10.28M | $11.37M | $12.07M | $8.71M |
| Other Liabilities | $- | $- | $1 | $- | $- | $- | $-23.90M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $346.52M | $55.07M | $49.05M | $48.82M | $51.66M | $43.83M | $11.16M | $30.79M | $36.03M | $28.37M | $21.93M | $22.34M | $27.44M | $27.39M | $26.34M | $34.28M | $36.31M | $33.07M | $30.63M | $23.26M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $8.00K | $8.00K | $8.00K | $8.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $6.00K | $6.00K | $5.00K |
| Retained Earnings | $-895.42M | $-876.21M | $-821.80M | $-770.96M | $-721.44M | $-678.65M | $-640.05M | $-602.88M | $-568.81M | $-535.69M | $-500.19M | $-465.42M | $-432.97M | $-400.23M | $-366.86M | $-333.20M | $-302.50M | $-276.34M | $-252.57M | $-232.09M |
| Accumulated Other Comprehensive Income Loss | $764.00K | $1.12M | $-463.00K | $-816.00K | $-1.27M | $-3.54M | $-5.22M | $-5.90M | $-8.03M | $-9.42M | $-7.82M | $-6.65M | $-1.79M | $-194.00K | $-393.00K | $-82.00K | $46.00K | $224.00K | $557.00K | $561.00K |
| Other Total Stockholders Equity | $1.31B | $1.30B | $1.29B | $1.28B | $1.12B | $1.11B | $1.10B | $1.00B | $997.11M | $964.72M | $957.49M | $948.31M | $941.36M | $934.17M | $925.80M | $919.26M | $913.35M | $582.61M | $574.38M | $434.72M |
| Total Stockholders Equity | $413.64M | $423.77M | $466.07M | $505.08M | $397.27M | $429.94M | $-640.05M | $-602.88M | $-568.81M | $419.62M | $449.49M | $476.25M | $506.61M | $533.76M | $558.55M | $585.99M | $610.90M | $306.50M | $322.37M | $203.20M |
| Total Equity | $413.64M | $423.77M | $466.07M | $505.08M | $397.27M | $429.94M | $-640.05M | $-602.88M | $-568.81M | $419.62M | $449.49M | $476.25M | $506.61M | $533.76M | $558.55M | $585.99M | $610.90M | $306.50M | $322.37M | $203.20M |
| Total Liabilities and Stockholders Equity | $760.16M | $478.84M | $515.12M | $553.91M | $448.94M | $473.77M | $-604.99M | $-572.09M | $-532.78M | $447.99M | $471.43M | $498.58M | $534.05M | $561.14M | $584.89M | $620.26M | $647.21M | $339.57M | $353.00M | $226.46M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $760.16M | $478.84M | $515.12M | $553.91M | $448.94M | $473.77M | $-604.99M | $-572.09M | $-532.78M | $447.99M | $471.43M | $498.58M | $534.05M | $561.14M | $584.89M | $620.26M | $647.21M | $339.57M | $353.00M | $226.46M |
| Total Investments | $502.93M | $405.82M | $446.54M | $485.82M | $386.84M | $423.85M | $427.86M | $378.84M | $386.18M | $336.84M | $411.00M | $446.24M | $427.29M | $504.26M | $528.52M | $493.04M | $307.83M | $248.46M | $204.11M | $183.12M |
| Total Debt | $16.59M | $16.63M | $16.73M | $16.97M | $17.20M | $17.42M | $13.04M | $13.54M | $14.02M | $5.38M | $5.89M | $6.39M | $6.88M | $7.35M | $6.74M | $13.80M | $14.98M | $15.43M | $15.26M | $7.50M |
| Net Debt | $-207.87M | $-32.85M | $-28.45M | $-24.54M | $-20.12M | $-11.32M | $-36.08M | $-13.52M | $-37.78M | $-85.55M | $-33.37M | $-27.44M | $-83.80M | $-31.83M | $-32.24M | $-97.04M | $-310.52M | $-61.53M | $-119.49M | $-26.31M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-173.98M | $-152.63M | $-135.84M | $-130.47M | $-89.62M |
| Depreciation and Amortization | $848.00K | $849.00K | $759.00K | $558.00K | $194.00K |
| Deferred Income Tax | $- | $- | $- | $4.60M | $- |
| Stock Based Compensation | $33.90M | $28.08M | $26.32M | $23.58M | $12.81M |
| Change in Working Capital | $286.17M | $7.82M | $-2.98M | $-3.22M | $6.38M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $15.20M | $- | $-802.00K | $-2.52M | $5.68M |
| Other Working Capital | $270.97M | $7.82M | $-2.18M | $-706.00K | $707.00K |
| Other Non Cash Items | $-12.62M | $-8.94M | $1.68M | $399.00K | $410.00K |
| Net Cash Provided by Operating Activities | $134.32M | $-124.82M | $-110.06M | $-104.55M | $-69.83M |
| Investments in Property Plant and Equipment | $-472.00K | $-168.00K | $-626.00K | $-1.15M | $-2.17M |
| Acquisitions Net | $- | $- | $-33.25K | $125.69K | $97.77K |
| Purchases of Investments | $-659.05M | $-409.82M | $-270.65M | $-445.66M | $-320.96M |
| Sales Maturities of Investments | $557.93M | $425.55M | $303.91M | $319.97M | $223.20M |
| Other Investing Activities | $- | $- | $33.25K | $-125.69K | $-97.77K |
| Net Cash Used for Investing Activities | $-101.59M | $15.56M | $32.63M | $-126.83M | $-99.94M |
| Debt Repayment | $- | $- | $10.00M | $-7.25M | $-250.00K |
| Common Stock Issued | $145.81M | $93.58M | $24.72M | $4.43M | $459.33M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $8.60M | $1.21M | $3.84M | $-611.00K | $10.25M |
| Net Cash Used Provided by Financing Activities | $154.42M | $94.78M | $38.56M | $-3.44M | $469.33M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $187.14M | $-14.48M | $-38.87M | $-234.82M | $299.57M |
| Cash at End of Period | $224.46M | $37.32M | $52.01M | $90.88M | $325.70M |
| Cash at Beginning of Period | $37.32M | $51.80M | $90.88M | $325.70M | $26.14M |
| Operating Cash Flow | $134.32M | $-124.82M | $-110.06M | $-104.55M | $-69.83M |
| Capital Expenditure | $-472.00K | $-168.00K | $-626.00K | $-1.15M | $-2.17M |
| Free Cash Flow | $133.84M | $-124.99M | $-110.69M | $-105.70M | $-72.00M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-19.22M | $-54.40M | $-50.84M | $-49.52M | $-42.79M | $-38.60M | $-37.17M | $-34.07M | $-33.11M | $-35.50M | $-34.77M | $-32.45M | $-32.74M | $-33.37M | $-33.66M | $-30.69M | $-26.16M | $-23.77M | $-20.49M | $-19.21M |
| Depreciation and Amortization | $204.00K | $-10.05M | $202.00K | $234.00K | $214.00K | $216.00K | $213.00K | $206.00K | $206.00K | $193.00K | $183.00K | $177.00K | $166.00K | $160.00K | $124.00K | $108.00K | $108.00K | $74.00K | $12.00K | $-110.00K |
| Deferred Income Tax | $- | $- | $- | $- | $5.00M | $-2.89M | $-2.11M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $110.00K |
| Stock Based Compensation | $8.63M | $8.32M | $8.43M | $8.51M | $7.17M | $7.09M | $6.99M | $6.84M | $6.80M | $6.36M | $6.51M | $6.65M | $6.40M | $6.11M | $5.99M | $5.08M | $3.74M | $3.36M | $2.55M | $3.15M |
| Change in Working Capital | $282.26M | $1.82M | $3.10M | $-4.92M | $3.71M | $5.04M | $6.35M | $-7.28M | $154.00K | $7.58M | $-3.06M | $-7.66M | $1.60M | $1.31M | $-2.28M | $-3.86M | $3.63M | $3.19M | $3.21M | $-3.65M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.00K | $- | $- | $-1.00K |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-2.47M | $- | $- | $-1.48M |
| Accounts Payables | $- | $5.68M | $-50.00K | $-3.13M | $7.65M | $3.93M | $4.11M | $-5.36M | $4.79M | $- | $-5.59M | $-5.25M | $-2.52M | $139.00K | $-1.24M | $-1.45M | $5.68M | $- | $- | $-2.39M |
| Other Working Capital | $282.26M | $-3.86M | $3.15M | $-1.79M | $-3.94M | $1.10M | $2.23M | $-1.91M | $-4.64M | $1.23M | $2.54M | $-2.40M | $4.12M | $1.31M | $-2.28M | $-2.40M | $423.00K | $3.19M | $3.21M | $219.00K |
| Other Non Cash Items | $-2.75M | $10.87M | $5.46M | $8.96M | $-7.61M | $122.00K | $121.00K | $-1.57M | $-581.00K | $6.72M | $794.00K | $1.10M | $1.22M | $1.19M | $1.75M | $850.00K | $368.00K | $176.00K | $-12.00K | $-110.00K |
| Net Cash Provided by Operating Activities | $269.13M | $-43.44M | $-42.53M | $-48.84M | $-34.31M | $-29.03M | $-25.62M | $-35.87M | $-26.53M | $-21.01M | $-30.34M | $-32.18M | $-23.37M | $-24.59M | $-28.07M | $-28.52M | $-18.31M | $-16.97M | $-14.73M | $-19.82M |
| Investments in Property Plant and Equipment | $-372.00K | $- | $-16.00K | $-84.00K | $-16.00K | $-20.00K | $-96.00K | $-36.00K | $-12.00K | $-381.00K | $-184.00K | $-49.00K | $-102.00K | $-723.00K | $-291.00K | $-31.00K | $-275.00K | $-665.00K | $-720.00K | $-511.00K |
| Acquisitions Net | $- | $- | $- | $- | $-26.49K | $-8.58K | $46.23K | $-11.16K | $47.31K | $- | $-33.28K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-240.58M | $-61.73M | $-161.67M | $-195.06M | $-99.69M | $-96.67M | $-139.63M | $-73.83M | $-106.12M | $-56.95M | $-56.18M | $-51.40M | $-16.34M | $-76.23M | $-129.93M | $-223.16M | $-128.02M | $-96.12M | $-85.54M | $-11.27M |
| Sales Maturities of Investments | $146.00M | $107.26M | $204.86M | $99.81M | $141.90M | $105.25M | $93.40M | $85.00M | $58.82M | $129.14M | $89.46M | $26.49M | $90.50M | $99.50M | $93.00M | $36.97M | $68.11M | $51.27M | $64.58M | $39.25M |
| Other Investing Activities | $- | $- | $43.18M | $-95.25M | $26.49K | $8.58K | $-46.23K | $11.16K | $-47.31K | $72.19M | $33.28K | $-24.91M | $74.16M | $23.27M | $-36.93M | $-186.19M | $-59.91M | $-44.85M | $-20.97M | $27.97M |
| Net Cash Used for Investing Activities | $-94.95M | $45.53M | $43.17M | $-95.34M | $42.20M | $8.56M | $-46.33M | $11.13M | $-47.32M | $71.81M | $33.10M | $-24.96M | $74.06M | $22.55M | $-37.22M | $-186.22M | $-60.19M | $-45.52M | $-21.69M | $27.46M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $10.00M | $- | $- | $- | $- | $- | $-6.50M | $-750.00K | $- | $- | $- | $- |
| Common Stock Issued | $-1.00K | $-5.59M | $3.04M | $145.81M | $691.00K | $84.00K | $93.58M | $- | $21.75M | $- | $2.97M | $303.00K | $4.43M | $2.26M | $545.00K | $829.00K | $324.33M | $-180.00K | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $807.00K | $2.20M | $3.04M | $2.56M | $691.00K | $84.00K | $431.00K | $- | $24.71M | $880.00K | $2.67M | $303.00K | $794.00K | $2.26M | $-66.00K | $829.00K | $2.70M | $4.68M | $137.37M | $247.00K |
| Net Cash Used Provided by Financing Activities | $806.00K | $2.20M | $3.04M | $148.37M | $691.00K | $84.00K | $94.01M | $- | $34.71M | $880.00K | $2.67M | $303.00K | $794.00K | $2.26M | $-6.57M | $79.00K | $327.04M | $4.68M | $137.37M | $247.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-3.94M | $22.88M | $-18.93M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $174.98M | $4.30M | $3.68M | $4.19M | $8.58M | $-20.59M | $22.07M | $-24.74M | $-39.13M | $51.68M | $5.42M | $-56.84M | $51.49M | $209.00K | $-71.86M | $-214.66M | $248.54M | $-57.80M | $100.95M | $7.89M |
| Cash at End of Period | $224.46M | $49.48M | $45.18M | $41.51M | $37.32M | $28.74M | $49.33M | $27.27M | $52.01M | $91.15M | $39.47M | $34.04M | $90.88M | $39.39M | $39.18M | $111.05M | $325.70M | $77.17M | $134.97M | $34.02M |
| Cash at Beginning of Period | $49.48M | $45.18M | $41.51M | $37.32M | $28.74M | $49.33M | $27.27M | $52.01M | $91.15M | $39.47M | $34.04M | $90.88M | $39.39M | $39.18M | $111.05M | $325.70M | $77.17M | $134.97M | $34.02M | $26.14M |
| Operating Cash Flow | $269.13M | $-43.44M | $-42.53M | $-48.84M | $-34.31M | $-29.03M | $-25.62M | $-35.87M | $-26.53M | $-21.01M | $-30.34M | $-32.18M | $-23.37M | $-24.59M | $-28.07M | $-28.52M | $-18.31M | $-16.97M | $-14.73M | $-19.82M |
| Capital Expenditure | $-372.00K | $- | $-16.00K | $-84.00K | $-16.00K | $-20.00K | $-96.00K | $-36.00K | $-12.00K | $-381.00K | $-184.00K | $-49.00K | $-102.00K | $-723.00K | $-291.00K | $-31.00K | $-275.00K | $-665.00K | $-720.00K | $-511.00K |
| Free Cash Flow | $268.76M | $-43.44M | $-42.55M | $-48.93M | $-34.32M | $-29.05M | $-25.71M | $-35.91M | $-26.54M | $-21.39M | $-30.52M | $-32.23M | $-23.47M | $-25.32M | $-28.36M | $-28.55M | $-18.58M | $-17.63M | $-15.45M | $-20.33M |
Kura Oncology Dividends
Explore Kura Oncology's dividend history, including dividend yield, payout ratio, and historical payments.
Kura Oncology News
Read the latest news about Kura Oncology, including recent articles, headlines, and updates.
Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting
– Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and cabozantinib in patients with RCC in 2H 2025 – SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that an abstract containing preclinical data for KO-2806, the Company's next-generation farnesyl transferase inhibitor (FTI), in combination with cabozantinib, a tyrosine kinase inhibitor (TKI), in clear cell renal cell carcinoma (ccRCC), has been accepted for an oral presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL on April 29, 2025. “The latest findings for our next-generation farnesyl transferase inhibitor, KO-2806, being presented at this year's AACR Annual Meeting, add to the growing body of data demonstrating the potential of FTIs as companion therapeutic agents to augment the antitumor activities of various targeted therapies and to overcome resistance in combination,” said Francis Burrows, Ph.D.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 3, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 190,000 shares of common stock to six (6) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity
Kura Oncology's ziftomenib shows promise in AML treatment, with key data readouts expected in 2025, but faces competition from Syndax's revumenib. Kura's strong cash position supports operations through 2027, bolstered by a lucrative deal with Kyowa Kirin, despite a 50/50 profit share. Market sentiment is low due to second-mover disadvantage and delayed catalysts, but current valuations present a potential buying opportunity.
Kura Oncology, Inc. (KURA) Q4 2024 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Patti Bank - IR Troy Wilson - President and CEO Mollie Leoni - CMO Tom Doyle - SVP of Finance and Accounting Brian Powl - CCO Conference Call Participants Li Watsek - Cantor Fitzgerald Yen-Der Li - Leerink Partners Jason Zemansky - Bank of America Peter Lawson - Barclays Dara Azar - Stifel Charles Zhu - LifeSci Capital David Dai - UBS Justin Zelin - BTIG George Farmer - Scotiabank Operator Good day, everyone, and welcome to today's Q4 2024 Kura Oncology, Inc. Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results
– KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR endpoint for potential U.S. accelerated approval pathway in frontline intensive chemotherapy trial – – Topline MRD-negative CR results from KOMET-017-IC Phase 3 trial anticipated in 2028 – – Multiple data presentations for ziftomenib and pipeline programs expected throughout 2025 – – $727.4 million in cash, together with anticipated collaboration agreement payments, to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2024 financial results and provided a corporate update.
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences:
Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2024 financial results after the close of U.S. financial markets on Wednesday, February 26, 2025. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs
– KOMET-001 registrational trial in R/R NPM1-m AML achieved primary CR/CRh endpoint; topline data submitted for presentation at an upcoming medical meeting –
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)
Kura Oncology, Inc.'s collaboration with Kyowa Kirin brings $330M upfront and a potential $1.2B in milestone payments, enhancing long-term shareholder value despite initial market disappointment. Ziftomenib, Kura's lead candidate, shows promising results in AML treatment, with a 35% complete remission rate, and could address up to 50% of AML patients. The stock is upgraded to Strong Buy due to its deep value, strong pipeline performance, and potential for substantial upside if FDA approval and commercialization go according to plan.
Kura Oncology to Host Virtual Investor Event on December 9, 2024
Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the upcoming JMP Securities Hematology and Oncology Summit. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 2:00 p.m. ET / 11:00 a.m. PT on December 2, 2024.
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors – – Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura to lead U.S. development and commercial activities and book sales; Kyowa Kirin has exclusive commercialization rights outside the U.S. – – Companies to jointly pursue broad development program targeting acute leukemias, including frontline indications, combinations with targeted therapies and post-transplant maintenance setting – – Kura anticipates collaboration funding along with current cash balance to support AML program advances through commercialization in frontline combination therapy – SAN DIEGO and TOKYO , Nov. 20, 2024 /PRNewswire/ -- Kura Oncology, Inc. (Nasdaq: KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced they have entered into a global strategic collaboration to develop and commercialize ziftomenib, Kura's selective oral menin inhibitor, being investigated for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies.
Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Pete De Spain - Head, Investor Relations Dr. Troy Wilson - President and CEO Tom Doyle - Senior Vice President, Finance and Accounting Dr. Mollie Leoni - Executive Vice President, Clinical Development Conference Call Participants Li Watsek - Cantor Jonathan Chang - Leerink Partners Jason Zemansky - Bank of America Roger Song - Jefferies Charles Zhu - LifeSci Capital Phil Nadeau - TD Cowen Peter Lawson - Barclays Justin Zelin - BTIG Brad Canino - Stifel Operator Good afternoon, ladies and gentlemen. Welcome to the Kura Oncology Third Quarter 2024 Financial Results Call.
Kura Oncology to Report Third Quarter 2024 Financial Results
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2024 financial results after the close of U.S. financial markets on Thursday, November 7, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
– New preclinical data to be presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics – – New preclinical data to be presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics –
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 study manuscript in The Lancet Oncology journal. The paper, entitled “Ziftomenib in relapsed/refractory acute myeloid leukaemia (KOMET-001): results from an open-label, multi-cohort, phase 1a/1b trial,” is now available on The Lancet Oncology website and in the Scientific Manuscripts section on Kura's website.
Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles is an accomplished biopharmaceutical executive with more than 25 years of oncology drug development experience and industry leadership.
Kura Oncology, Inc. (KURA) Q2 2024 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Pete De Spain - Head, IR Troy Wilson - President and CEO Thomas Doyle - SVP of Finance and Accounting Conference Call Participants Li Watsek - Cantor Fitzgerald Jonathan Chang - Leerink Partners Cameron Bozdog - Bank of America Roger Song - Jefferies Brad Canino - Stifel Phil Nadeau - TD Cowen Alex Bouilloux - Barclays Justin Zelin - BTIG George Farmer - Scotiabank Operator Good day, and welcome to the Q2 2024 Kura Oncology Conference Call. [Operator Instructions] Please note this event is being recorded.
Kura Oncology to Report Second Quarter 2024 Financial Results
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2024 financial results after the close of U.S. financial markets on Thursday, August 8, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for KURA.